TREO支架移植物腔内治疗腹主动脉瘤的安全性与有效性
这项多中心、非随机、研究性器械豁免临床试验评估了TREO支架移植物治疗肾下腹主动脉瘤或主髂动脉瘤的安全性和有效性。150例患者(88.0%男性)纳入,30天主要不良事件发生率为0.7%,1年成功动脉瘤治疗比例为93.1%。3年随访全因累积死亡率为10.7%,I型内漏发生率为2.7%,III型内漏为0%,54.3%患者动脉瘤囊缩小>5 mm,9.3%需二次干预。
要点
- TREO支架30天主要不良事件发生率低(0.7%)。
- 1年成功动脉瘤治疗率达93.1%,3年动脉瘤囊缩小>5 mm者占54.3%。
- 3年I型内漏发生率2.7%,III型为0%,9.3%需二次干预。
核心结论
- TREO支架腔内修复腹主动脉瘤的安全性和有效性得到证实,1年成功治疗率93.1%,3年54.3%患者动脉瘤囊缩小>5 mm。
研究设计与样本
- 多中心、非随机、研究性器械豁免临床试验,纳入150例肾下腹主动脉瘤(87.3%)或主髂动脉瘤(12.7%)患者,平均年龄71.7±7.4岁,男性132例(88.0%)。
主要发现
- 30天主要不良事件发生率为0.7%,1例受试者发生心肌梗死和术中失血1000 mL两起事件。
- 1年成功动脉瘤治疗比例为93.1%。
- 3年累积全因死亡率为10.7%(n=16),I型内漏发生率为2.7%(n=4),III型内漏发生率为0%(n=0)。
- 3年动脉瘤囊缩小>5 mm者占54.3%,9.3%(n=14)患者需二次干预。
- 最新随访无动脉瘤相关死亡。
临床怎么用
- TREO支架可作为肾下腹主动脉瘤或主髂动脉瘤腔内修复的选项,短期安全性和有效性良好。
- 术后需长期随访监测内漏、动脉瘤囊变化及二次干预需求。
局限性
- 研究为非随机设计,长期随访仍在进行中,尚不能确定有利结果能否持续。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The short- and mid-term outcomes of endovascular aortic aneurysm repair have made it a standard treatment of abdominal aortic aneurysms. However, newer generation devices have yet to demonstrate improved long-term rates for complications, reinterventions, and survival. The TREO stent graft is a latest generation device and was evaluated for approval in the United States. METHODS: In a multicenter, nonrandomized, investigational device exemption clinical trial, we assessed the safety and effectiveness of the TREO device, with core laboratory assessment of the imaging studies and an independent adjudication of safety. The primary effectiveness endpoint was successful aneurysm treatment at 1 year. The primary safety endpoint was the incidence of major adverse events (MAE) at 30 days. RESULTS: A total of 150 patients (132 men; 88.0%) with infrarenal abdominal aortic (87.3%) or aortoiliac (12.7%) aneurysms were enrolled. The data were normally distributed. The mean age was 71.7 ± 7.4 years. The MAE incidence at 30 days was 0.7%. One subject experienced two MAE: myocardial infarction and procedural blood loss of 1000 mL. The proportion of successful aneurysm treatment at 1 year was 93.1%. Longer term follow-up continues, with no aneurysm-related mortality at the latest follow-up. At 3 years, the cumulative all-cause mortality and incidence of type I and type III endoleaks was 10.7% (n = 16), 2.7% (n = 4), and 0% (n = 0), respectively. In addition, aneurysm sac shrinkage >5 mm at 3 years had occurred in 54.3% of patients, and 9.3% had required a secondary intervention (n = 14). CONCLUSIONS: The safety and effectiveness of endovascular repair of abdominal aneurysms with TREO were demonstrated, with 93.1% successful aneurysm treatment at 1 year and aneurysm sac shrinkage >5 mm at 3 years in 54.3% of patients. Long-term follow-up continues to determine whether these favorable outcomes will be sustained.
引用
- Eagleton MJ, Stoner M, Henretta J, et al. Safety and effectiveness of the TREO stent graft for the endovascular treatment of abdominal aortic aneurysms. J Vasc Surg. 2020. PMID: 33253871. doi:10.1016/j.jvs.2020.10.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。